Related Experiment Video
Updated: Mar 16, 2026
09:52
Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq
Published on: April 19, 2013
24.9K
Pharmacogenetic studies update in type 2 diabetes mellitus
Shalini Singh1, Kauser Usman1, Monisha Banerjee1
1Shalini Singh, Monisha Banerjee, Molecular and Human Genetics Laboratory, Department of Zoology, University of Lucknow, Lucknow 226007, India.
World Journal of Diabetes
|August 25, 2016
Summary
Genetic variations influence how individuals respond to type 2 diabetes medications. Pharmacogenetics helps personalize oral antidiabetic drug (OAD) therapy, improving treatment efficacy and patient outcomes.
Area of Science:
- Pharmacogenetics
- Metabolic Disorders
- Personalized Medicine
Background:
- Type 2 diabetes mellitus (T2DM) is a progressive metabolic disorder affecting millions globally, necessitating optimized glycemic control to prevent complications.
- Current treatments for T2DM involve various oral antidiabetic drugs (OADs), but individual responses vary significantly.
- Genetic variations are known to influence T2DM risk and predict personalized responses to drug therapies.
Purpose of the Study:
- To explore the role of pharmacogenetics in understanding inter-individual variability in response to OADs.
- To highlight the clinical utility of pharmacogenetic studies in optimizing T2DM treatment.
- To position pharmacogenetics as a key component of personalized medicine for diabetes.
Main Methods:
- Review of genetic polymorphisms in genes encoding drug receptors, transporters (e.g., SLC family), and metabolizing enzymes (e.g., CYP family).
- Analysis of the impact of these genetic variants on the efficacy and safety of OADs.
- Examination of pharmacogenetic study findings related to glycemic control and HbA1c management.
Main Results:
- Genetic variants in solute carrier transporters (SLC22A1, SLC22A2, SLC22A3, SLC47A1, SLC47A2) affect metformin's glycemic management.
- Cytochrome P450 (CYP) gene polymorphisms influence the metabolism of various OADs.
- Pharmacogenetic studies demonstrate a clear link between genetic makeup and variable therapeutic outcomes with OADs.
Conclusions:
- Pharmacogenetics provides crucial insights into individual responses to OADs, explaining treatment variability.
- Identifying specific genetic variants can predict optimal therapeutic doses for OADs on an individual basis.
- Pharmacogenetics represents a significant advancement towards personalized medicine, promising improved efficacy in T2DM treatment.
Related Concept Videos
01:27Pharmacogenetics of Drug Metabolism: Overview
88
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
88
01:29Pharmacogenomics: Identification of New Drug Targets
73
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
73
01:27Principles of Pharmacogenetics: Types of Genetic Variants
73
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
73
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
94
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
94
01:29Pharmacogenetics and Pharmacogenomics: Overview
122
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
122
01:22Diabetes Mellitus: Type 2 and Gestational
5.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.3K